Gilead sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 clinical study assessing the combination of islatravir and lenacapavir for viral suppression in HIV treatment.

Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), including a CGM sensor and two apps designed to present current glucose values and predictions over 30 minutes and two hours.

GSK has announced positive results from part 1 and part 2 of its ruby/engot-en6/gog3031/ nsgo phase 3 trial for Jemperli (dostarlimab) in combinations for the treatment of adult patients with primary advanced or recurrent endometrial cancer.

Merck, known as MSD outside of the US and Canada, has announced positive results from the phase 3 KEYNOTE-a18 trial, which investigates Keytruda in combination with chemoradiotherapy for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer.

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study of Amlitelimab for adult patients with moderate-to-severe atopic dermatitis (ad) who previously responded to Amlitelimab and continued treatment.

Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel ep4 receptor agonist, HTL0033744 (htl’744) for the treatment of inflammatory bowel disease (IBD).

Bayer and AIgnostics have announced that they have entered into a strategic collaboration for several artificial intelligence (AI)-powered approaches for precision oncology drug research and development.

Johnson & Johnson (J&J) MedTech has announced that it is working in collaboration with NVIDIA to accelerate and scale artificial intelligence (AI) for use in surgeries.

Merck, known as MSD outside of the US and Canada, has announced that it is planning to initiate clinical development of a new investigational multivalent human papillomavirus (HPV) vaccine, as well as assessing a single-dose regimen of Gardasil 9 compared to its approved three-dose regimen.

Allumiqs and Prolytix have announced that they have entered into a long-term, strategic partnership with the aim of providing collaborative and integrated solutions for their customers to optimise drug development pipelines.

Freenome has announced that it has raised $254m from new and existing investors, intended to be used for the advancement of its single-cancer and tailored multi-cancer early detection tests developed on its multiomics platform.

Roche has announced data from stage 1 of the NIH-sponsored phase 3 outmatch trial, which assessed the safety and efficacy of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods.